ライフサイエンスコーパス: antiplatelet therapy

1 o metallic stents (mechanical and inadequate antiplatelet therapy).

2 l outcomes than those who were not receiving antiplatelet therapy.

3 feasible approach for patients needing dual antiplatelet therapy.

4 ed with aspirin alone or short duration dual antiplatelet therapy.

5 ted patients and 25.7 for patients receiving antiplatelet therapy.

6 participants to different durations of dual antiplatelet therapy.

7 40%) did not receive standard post-TAVI dual-antiplatelet therapy.

8 are-metal stents followed by 1 month of dual antiplatelet therapy.

9 e cases and a moderate recurrence rate under antiplatelet therapy.

10 ated patients and 5.3 for patients receiving antiplatelet therapy.

11 tivation and aggregation in patients on dual antiplatelet therapy.

12 All patients received 1 month of dual antiplatelet therapy.

13 ints when used with a 1-month course of dual antiplatelet therapy.

14 higher risk of bleeding from prolonged dual antiplatelet therapy.

15 ly increased for VKA with and without single-antiplatelet therapy.

16 g smokers observed in trials evaluating dual antiplatelet therapy.

17 p guide post-coronary artery bypass grafting antiplatelet therapy.

18 tilization of this marker for individualized antiplatelet therapy.

19 d dipyridamole) with that of guideline-based antiplatelet therapy.

20 clinical practice, requiring prolonged dual antiplatelet therapy.

21 cker treatment, and a neutral effect of dual antiplatelet therapy.

22 tent (DCS) or a BMS followed by 1-month dual antiplatelet therapy.

23 ional, and clinical sciences in the field of antiplatelet therapy.

24 n receptor blockers, beta-blockers, and dual antiplatelet therapy.

25 erent risks and benefits with prolonged dual antiplatelet therapy.

26 closure or anticoagulation, as compared with antiplatelet therapy.

27 s comprehensive risk factor modification and antiplatelet therapy.

28 ts with acute coronary syndrome on different antiplatelet therapies.

29 splay adverse thrombotic events with current antiplatelet therapies.

30 d during continued treatment with background antiplatelet therapies.

31 on test be used to guide the dose or type of antiplatelet therapy?

32 [4%] of 224) than among those receiving dual antiplatelet therapy (31 [15%] of 208; p<0.0001); NOACs

33 Most patients receiving antiplatelet therapy (3613 of 4527 [80%]) received low-d

34 ate of sICH was higher in patients receiving antiplatelet therapy (5.0% vs 3.7%).

35 : 0.84; 95% CI: 0.83 to 0.86; p < 0.001) and antiplatelet therapy (79.0% vs. 84.6%; RR: 0.93; 95% CI:

36 particularly high in patients receiving dual antiplatelet therapy (adjusted HR, 5.21; 95% CI, 1.24-21

37 : 1.00: 95% CI: 0.99 to 1.01; p = 0.772) and antiplatelet therapy (adjusted RR: 1.00; 95% CI: 0.99 to

38 The choice of antiplatelet therapy after acute coronary syndrome (ACS)

39 rapy with P2Y12 inhibitors alone versus dual-antiplatelet therapy after acute coronary syndromes or c

40 etween those who were and were not receiving antiplatelet therapy after adjustment (8.0% vs 6.6%; AOR

41 ients receiving RBC compared to those not on antiplatelet therapy after adjustment for confounders, C

42 The benefit and need for prolonged dual antiplatelet therapy after bioresorbable scaffold implan

43 t benefit from more aggressive and prolonged antiplatelet therapy after CAS.

44 trial, compared 30 versus 12 months of dual antiplatelet therapy after coronary stenting.

45 In the debate about the duration of dual antiplatelet therapy after drug-eluting stent implantati

46 ndation ("may be considered") to extend dual antiplatelet therapy after drug-eluting stent implantati

47 fety bolsters the argument for personalizing antiplatelet therapy after PCI on the basis of the patie

48 sting is currently not recommended to tailor antiplatelet therapy after PCI.

49 Dual antiplatelet therapy after percutaneous coronary interve

50 proximately 10% of patients who receive dual antiplatelet therapy after percutaneous coronary interve

51 Individualizing antiplatelet therapy after platelet function testing did

52 nts received short-term (1 to 3 months) dual-antiplatelet therapy after the procedure and single-anti

53 treatment, oral anticoagulant treatment, or antiplatelet therapy) after the intracranial hemorrhage.

54 In the DAPT Study (Dual Antiplatelet Therapy), after percutaneous coronary inter

55 rm antiplatelet therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or

56 et therapy (PFO closure group) or to receive antiplatelet therapy alone (antiplatelet-only group).

57 re combined with antiplatelet therapy versus antiplatelet therapy alone on the risks of recurrent str

58 f PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined d

59 the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined d

60 gulants and in 7 of 174 patients assigned to antiplatelet therapy alone.

61 latelet therapy than among those assigned to antiplatelet therapy alone.

62 latelet therapy than among those assigned to antiplatelet therapy alone; however, PFO closure was ass

63 its and risks of 30 versus 12 months of dual antiplatelet therapy among patients undergoing coronary

64 nists could potentially be useful adducts in antiplatelet therapies and may provide a promising persp

65 elopment of strategies to improve on current antiplatelet therapies and to reduce cardiovascular dise

66 particularly high in patients receiving dual antiplatelet therapy and in the 1st year after stroke/TI

67 Continued dual antiplatelet therapy and optimal medical therapy (OMT) i

68 rombotic events following discontinuation of antiplatelet therapy and the risk of hemorrhagic complic

69 d not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monothe

70 th diabetes often show hyporesponsiveness to antiplatelet therapies, and it has been suggested that h

71 eceived coronary revascularization, 22% dual-antiplatelet therapy, and 71% high-dose statin therapy v

72 guided stenting, assiduous adherence to dual antiplatelet therapy, and adequate P2Y12 platelet recept

73 Five patients had discontinued dual antiplatelet therapy, and in 3 of them discontinued dual

74 otensin system blockers, beta-blockers, dual antiplatelet therapy, and long-term cardiovascular event

75 t era of drug-eluting stents, prolonged dual antiplatelet therapy, and potent P2Y12 inhibitors are no

76 ned to 1 of 3 groups, that is, no treatment, antiplatelet therapy, and warfarin.

77 ularly evident when VKA was combined with an antiplatelet therapy (APT).

78 The effects of single- and dual-antiplatelet therapy are also assessed.

79 in what has come to be commonly called dual antiplatelet therapy, are a mainstay of treatment for pa

80 years; 65% men; 75% diabetic) received dual antiplatelet therapy as a single loading dose (ticagrelo

81 tients were randomized (1:1) to receive dual antiplatelet therapy (aspirin + clopidogrel [the clopido

82 l [the clopidogrel group], n = 84) vs single antiplatelet therapy (aspirin + placebo [the placebo gro

83 Rates of dual antiplatelet therapy at 1 year were 32.2% for patients i

84 ary intervention and were discharged on dual-antiplatelet therapy at 228 US hospitals in the Treatmen

85 dherence patients described missing doses of antiplatelet therapy at least twice a week after percuta

86 s in patients receiving anticoagulant and/or antiplatelet therapy at the time of cataract surgery.

87 dies have investigated whether adjustment of antiplatelet therapies based on a single platelet functi

88 wever, many patients may have been receiving antiplatelet therapy before acute ischemic stroke and co

89 istry patients, 38844 (45.7%) were receiving antiplatelet therapy before admission; 46 228 patients (

90 latelet agents, and clinical indications for antiplatelet therapy before focusing on a frequent quest

91 inferior to standard care for people taking antiplatelet therapy before intracerebral haemorrhage.

92 reated with intravenous tPA, those receiving antiplatelet therapy before the stroke had a higher risk

93 Prestroke antiplatelet therapy before tPA administration for acute

94 Dual antiplatelet therapy beyond 1 year after placement of a

95 t Therapy (DAPT) Study, continuation of dual antiplatelet therapy beyond 12 months after coronary ste

96 patient benefit and harm from continued dual antiplatelet therapy beyond assessment of MI history alo

97 erapy refers to the contemporary approach of antiplatelet therapy, blood pressure control, low-densit

98 re, our data may support a novel approach to antiplatelet therapy by Src inhibition where hemostasis

99 However, antiplatelet therapy can be associated with an increased

100 In 682 patients not treated with antiplatelet therapy, circulating PCSK9 and 11-dh-TxB2 w

101 loading doses and then 30 days of intensive antiplatelet therapy (combined aspirin 75 mg, clopidogre

102 compare the safety and efficacy of intensive antiplatelet therapy (combined aspirin, clopidogrel, and

103 bosis, any bleeding, and major bleeding with antiplatelet therapy compared with none ranged from 0.26

104 iple organ failure among the group receiving antiplatelet therapy compared with those not receiving i

105 hematologists about the 2 most commonly used antiplatelet therapies: Could the patient be aspirin "re

106 ia) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months.

107 recent studies, the optimum duration of dual antiplatelet therapy (DAPT) after coronary drug-eluting

108 The appropriate duration of dual-antiplatelet therapy (DAPT) after drug-eluting stent (DE

109 The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DE

110 The optimal duration of dual antiplatelet therapy (DAPT) after implantation of newer-

111 effect of 30 months versus 12 months of dual antiplatelet therapy (DAPT) after percutaneous coronary

112 use of drug-eluting stents, and use of dual antiplatelet therapy (DAPT) at randomization.

113 Although dual antiplatelet therapy (DAPT) beyond 1 year provides ische

114 Dual antiplatelet therapy (DAPT) cessation increases the risk

115 The benefits and harms of dual antiplatelet therapy (DAPT) continuation beyond 1 year a

116 The optimal duration of dual antiplatelet therapy (DAPT) following second-generation

117 se of proton pump inhibitors (PPIs) and dual antiplatelet therapy (DAPT) for cardiovascular outcomes.

118 The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES)

119 ice guidelines recommend post-operative dual antiplatelet therapy (DAPT) in patients who undergo coro

120 dates regarding the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coron

121 nged (24 months) vs short (</=6 months) dual antiplatelet therapy (DAPT) in patients with PAD undergo

122 Whether premature dual antiplatelet therapy (DAPT) interruption is safe in pati

123 Dual antiplatelet therapy (DAPT) is prescribed to millions of

124 Prolonged dual antiplatelet therapy (DAPT) is recommended after an acut

125 Outcomes with dual antiplatelet therapy (DAPT) or triple therapy (DAPT plus

126 hort (6 months) versus long (24 months) dual antiplatelet therapy (DAPT) regimen.

127 The dual-antiplatelet therapy (DAPT) score was developed to ident

128 g patients with DM participating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified anal

129 analysis is derived from data from the Dual Antiplatelet Therapy (DAPT) Study, a multicenter trial i

130 In the Dual Antiplatelet Therapy (DAPT) Study, continuation of dual

131 lation with a vitamin K antagonist plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and a

132 Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 in

133 Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibi

134 with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to

135 tinal (GI) events in patients requiring dual antiplatelet therapy (DAPT).

136 stents (BMS) under similar durations of dual-antiplatelet therapy (DAPT).

137 The primary outcome was intensification in antiplatelet therapy defined as either dose escalation o

138 ts with recent cerebral ischaemia, intensive antiplatelet therapy did not reduce the incidence and se

139 therapy, and in 3 of them discontinued dual antiplatelet therapy discontinuation had occurred the we

140 Dual antiplatelet therapy discontinuation seems to also be a

141 eluting stents, which require prolonged dual antiplatelet therapy due to the increased risk of late a

142 tool (DAPT score) aids prescription of dual antiplatelet therapy duration in patients with or withou

143 e ischemic and bleeding risks to inform dual antiplatelet therapy duration showed modest accuracy in

144 neration and BMS, thus allowing shorter dual antiplatelet therapy duration.

145 d myocardial infarctions with prolonged dual antiplatelet therapy, findings that support the new Clas

146 For patients on dual antiplatelet therapy followed for 1 year, the hazard rat

147 In patients treated with dual antiplatelet therapy for at least 1 year after coronary

148 l haemorrhage symptom onset if they had used antiplatelet therapy for at least 7 days beforehand and

149 We therefore recommend serial imaging and antiplatelet therapy for iBCVI.

150 Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosc

151 ng P2Y12 antagonist and is widely used as an antiplatelet therapy for the prevention of cardiovascula

152 ded, randomized placebo-controlled trials of antiplatelet therapy for the prevention of ischemic even

153 risk of VTE by 29% compared with background antiplatelet therapy, from 0.93% to 0.64% at 3 years (ha

154 latelet therapy group, 1540 in the guideline antiplatelet therapy group) were recruited from 106 hosp

155 3096 participants (1556 in the intensive antiplatelet therapy group, 1540 in the guideline antipl

156 However, patients receiving antiplatelet therapy had a greater risk-adjusted likelih

157 In addition, antiplatelet therapy had a smaller risk (albeit not sign

158 Sex-specific differences in response to antiplatelet therapies have been described.

159 runs, earlier date of procedure, and no dual antiplatelet therapy; high pre-TAVR aortic peak gradient

160 0.04), and premature discontinuation of dual antiplatelet therapy (HR=2.67, P=0.003); high platelet r

161 The development of antiplatelet therapy illustrates the importance of under

162 trials evaluating the risks and benefits of antiplatelet therapies in patients with atherosclerosis.

163 llagen interaction combined with established antiplatelet therapies in patients with spontaneous plaq

164 on and symptoms of claudication was low: any antiplatelet therapy in 35.7% (standard error [SE]: 2.7%

165 ble evidence about the risk-benefit ratio of antiplatelet therapy in adults with ET is highly uncerta

166 me point might not be sufficient for guiding antiplatelet therapy in clinical or research settings.

167 were significantly more likely to intensify antiplatelet therapy in CYP2C19 allele carriers, but onl

168 attractive alternative to blocking PAR1 for antiplatelet therapy in humans.

169 o platelet aggregation before and after dual antiplatelet therapy in individuals (n=565) from the Pha

170 Dual antiplatelet therapy in older versus younger patients wi

171 ctical strategies for managing perioperative antiplatelet therapy in patients following percutaneous

172 ent data do not support routine PFT to guide antiplatelet therapy in patients undergoing nonurgent PC

173 controlled study to investigate alternative antiplatelet therapy in patients with aspirin resistance

174 ide an updated overview on the management of antiplatelet therapy in patients with coronary stents un

175 ent thrombotic events when added to standard antiplatelet therapy in patients with stable atheroscler

176 could be associated with high RPR after dual antiplatelet therapy in patients with stable coronary ar

177 clinical trials comparing anticoagulation to antiplatelet therapy in secondary stroke prevention.

178 Aspirin is still the mainstay of antiplatelet therapy in the secondary prevention of coro

179 occurred in patients who had suspended dual antiplatelet therapy, in 6 cases prematurely.

180 ssist device support; yet, their relation to antiplatelet therapy, including aspirin (ASA) dosing, is

181 f poor metabolizers of clopidogrel had their antiplatelet therapy intensified.

182 ial artery to aggressive medical management (antiplatelet therapy, intensive management of vascular r

183 A limitation of current antiplatelet therapies is their inability to separate th

184 ies acute coronary syndromes, and therefore, antiplatelet therapy is an important foundation in the t

185 Bleeding risk with antiplatelet therapy is an increasing clinical challenge

186 ent for confounders, CONCLUSIONS: Pre-injury antiplatelet therapy is associated with a decreased risk

187 al platelet reactivity (high RPR) after dual antiplatelet therapy is associated with increased cardio

188 rombosis history the benefit/risk profile of antiplatelet therapy is likely to be favorable, in those

189 However, long-term dual-antiplatelet therapy is linked to higher risk for ICH th

190 Antiplatelet therapy is of proven benefit in coronary ar

191 ions of having a surgical procedure while on antiplatelet therapy is pivotal.

192 Dual antiplatelet therapy is recommended after coronary stent

193 ed with biolimus-A9 followed by 1-month dual antiplatelet therapy is safer and more effective than a

194 Anticoagulant or antiplatelet therapy is the preferred treatment option f

195 er OMT modifies the treatment effect of dual antiplatelet therapy is unknown.

196 of DAPT after the procedure, and longer dual antiplatelet therapy (L-DAPT) was defined as the per-pro

197 ed with aspirin alone or short duration dual antiplatelet therapy (</=6 months), continued treatment

198 may play a key role in graft occlusion, and antiplatelet therapies may reduce ischemic events, but p

199 More potent and longer antiplatelet therapy may be beneficial for patients unde

200 The benefits and risks of prolonged dual antiplatelet therapy may be different for patients with

201 y intracerebral haemorrhage in people taking antiplatelet therapy might reduce death or dependence by

202 AD and CAD were more likely to be prescribed antiplatelet therapy (odds ratio [OR]: 2.6; 95% confiden

203 e comparison of the current standard of dual antiplatelet therapy of aspirin with clopidogrel versus

204 assess the effect of extended duration dual antiplatelet therapy on mortality by doing a meta-analys

205 botic therapy (27.1% [95% CI, 26.6%-27.7%]), antiplatelet therapy only (24.8% [95% CI, 24.3%-25.3%]),

206 rombotic therapy (9.3% [95% CI, 8.9%-9.6%]), antiplatelet therapy only (8.1% [95% CI, 7.8%-8.3%]), or

207 time of stroke, 37674 (39.9%) were receiving antiplatelet therapy only, and 28583 (30.3%) were not re

208 carriers to have an intensification of their antiplatelet therapy, only 20% of poor metabolizers of c

209 extended duration versus short duration dual antiplatelet therapy or aspirin alone.

210 cannot tolerate or have contraindications to antiplatelet therapy or in the setting of a subarachnoid

211 Antiplatelet therapy or selective inhibition of PDGFB mi

212 drug adjustment in suboptimal responders to antiplatelet therapy or to a conventional strategy witho

213 in a 2:1 ratio, to undergo PFO closure plus antiplatelet therapy (PFO closure group) or to receive a

214 to transcatheter PFO closure plus long-term antiplatelet therapy (PFO closure group), antiplatelet t

215 Fifteen percent were taking antiplatelet therapy prior to injury.

216 ly been studied in addition to aspirin; dual-antiplatelet therapy proved superiority compared with as

217 s of platelet dysfunction and currently used antiplatelet therapies provide a framework for understan

218 ed duration versus no or short duration dual antiplatelet therapy, published before Oct 1, 2014.

219 ternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3).

220 is, any bleeding, and major bleeding without antiplatelet therapy ranged from 5 to 110 (median, 20),

221 Do antiplatelet therapies reduce risk of all-cause mortalit

222 with 12 months of therapy, 30 months of dual antiplatelet therapy reduced the risk of stent thrombosi

223 More intensive antiplatelet therapy reduces the risk of VTE.

224 mptomatic atherosclerosis and more intensive antiplatelet therapy reduces VTE risk beyond aspirin mon

225 e comparable benefit from intensification of antiplatelet therapy remains uncertain.

226 n receptor blockers, beta-blockers, and dual antiplatelet therapy, respectively.

227 ene to be most strongly associated with dual antiplatelet therapy response (P=7.66x10(-9)).

228 of DAPT after DES implantation: shorter dual antiplatelet therapy (S-DAPT) was defined as the per-pro

229 ical trials, the perioperative management of antiplatelet therapy should be based on the balance betw

230 Triple antiplatelet therapy should not be used in routine clini

231 In contrast, antiplatelet therapy significantly reduced miRNA levels.

232 he proportion of visits with medication use (antiplatelet therapy, statins, angiotensin-converting en

233 New data from long-term dual antiplatelet therapy studies and investigations of antic

234 axel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 3

235 nary Syndrome (ACS)-Prospective, Open Label, Antiplatelet Therapy Study (TRANSLATE-POPS) was a cluste

236 (The Dual Antiplatelet Therapy Study [DAPT Study]; NCT00977938).

237 The Dual Antiplatelet Therapy Study is large streamlined clinical

238 The Dual Antiplatelet Therapy Study, a randomized double-blind, p

239 Within the Dual Antiplatelet Therapy Study, clinical trial sites had sim

240 ipating versus not participating in the Dual Antiplatelet Therapy Study.

241 f which 309 (24.2%) participated in the Dual Antiplatelet Therapy Study.

242 (The Dual Antiplatelet Therapy Study; NCT00977938).

243 The DAPT (Dual Antiplatelet Therapy) study enrolled patients after coro

244 The DAPT (Dual Antiplatelet Therapy) Study, a double-blind trial, rando

245 those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antipl

246 those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antipl

247 ut was greater among patients receiving dual-antiplatelet therapy than among those receiving clopidog

248 Compared with all antiplatelet therapies, the strongest evidence exists fo

249 stented patients who were treated with dual antiplatelet therapy, there was a mortality reduction am

250 telet therapy after the procedure and single-antiplatelet therapy thereafter.

251 The common practice of adding antiplatelet therapy to oral VKA anticoagulation in pati

252 gated the effectiveness and safety of adding antiplatelet therapy to vitamin K antagonist (VKA) in at

253 ble coronary artery disease, the addition of antiplatelet therapy to VKA therapy is not associated wi

254 sting HF and vascular disease, adding single-antiplatelet therapy to VKA therapy is not associated wi

255 nts (1:1; stratified by hospital and type of antiplatelet therapy) to receive either standard care or

256 on Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy) trial was a 1:1 randomized, multic

257 Dual antiplatelet therapy until surgery is beneficial, wherea

258 er intracerebral haemorrhage associated with antiplatelet therapy use.

259 Agents used in dual- and single-antiplatelet therapies varied across trials, and the rel

260 lusions regarding the safety and efficacy of antiplatelet therapy varied depending on analytic techni

261 ated the effect of PFO closure combined with antiplatelet therapy versus antiplatelet therapy alone o

262 More intensive antiplatelet therapy (vorapaxar and ticagrelor pooled) s

263 ts with coronary stenting receiving standard antiplatelet therapy, vorapaxar administered for long-te

264 sing the ACP device followed by dual-/single-antiplatelet therapy was associated with a low rate of e

265 eding use of therapeutic warfarin, NOACs, or antiplatelet therapy was associated with lower odds of m

266 By contrast, intensive antiplatelet therapy was associated with more, and more

267 Extended duration dual antiplatelet therapy was not associated with a differenc

268 ulation with warfarin, as compared with dual antiplatelet therapy, was associated with a decreased in

269 tion (both NOACs and warfarin), but not dual antiplatelet therapy, was effective in prevention or tre

270 on, and patients with an indication for dual antiplatelet therapy were excluded.

271 Patients receiving antiplatelet therapy were older (median [25th-75th perce

272 therapy (ie, oral anticoagulation plus dual antiplatelet therapy) were independent predictors of GIB

273 e than adults without diabetes, yet standard antiplatelet therapy, which is the cornerstone for prima

274 platelet transfusion for patients receiving antiplatelet therapy who have intracranial hemorrhage (t

275 The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was

276 eparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) and clo

277 Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor

278 Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor

279 Dual-antiplatelet therapy with aspirin and clopidogrel after

280 The effects of dual antiplatelet therapy with aspirin and clopidogrel on the

281 t (DES) implantation require additional dual antiplatelet therapy with aspirin and clopidogrel.

282 or cytotoxic agents (high-risk patients) and antiplatelet therapy with aspirin.

283 post hoc analysis of the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES

284 The Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES

285 Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES

286 large-scale, prospective Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents study.

287 d in the ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) according

288 rformed in the ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) registry.

289 he prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) study was

290 ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was a lar

291 METHODS AND ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was a pro

292 ticenter ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) were stra

293 ROMETHEUS, ADAPT-DES [the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents], THIN [Th

294 investigation includes evaluation of single-antiplatelet therapy with P2Y12 inhibitors alone versus

295 The optimal duration of dual antiplatelet therapy with prasugrel after TAXUS Liberte

296 Intensive antiplatelet therapy with three agents might be more eff

297 tation after loading and maintenance of dual antiplatelet therapy with ticagrelor and the influence o

298 of this study was to determine the effect of antiplatelet therapy with ticagrelor on recurrent ischem

299 determine whether the efficacy and safety of antiplatelet therapy with vorapaxar was modified by conc

300 ronary stenting and completed 1 year of dual antiplatelet therapy without major bleeding or ischemic